Evidence map›Paper›PMID 18562131›Full record

Trial reportDrug and alcohol dependence2008

Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses.

Sean P David, Elaine C Johnstone, Michael F G Murphy, Paul Aveyard, Boliang Guo, Caryn Lerman, Marcus R Munafò

Open access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013
    Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2011
    Review
  12. Article
  13. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Sean P DavidDepartment of Family Medicine, Center for Primary Care & Prevention, The Warren Alpert Medical School of Brown University, 111 Brewster Street, Pawtucket, RI 02806, USA. Sean_David@Brown.edu
Elaine C Johnstone
Michael F G Murphy
Paul Aveyard
Boliang Guo
Caryn Lerman
Marcus R Munafò
University of Birmingham · GBUniversity of Oxford · GBBrown University · USUniversity of Bristol · GBUniversity of Pennsylvania · US

Funding

Psychobiological /Genetic Determinants-Smoking CessationK08DA014276 · NIDA · MEMORIAL HOSPITAL OF RHODE ISLAND · PI DAVID, SEAN P. · 2002 to 2006
$786k
Cancer Research UKNIDA NIH HHS 1K08 DA14276-05NIDA NIH HHS K08 DA014276PHS HHS P5084718
6 · The paper itself

Abstract

The serotonin pathway has been implicated in nicotine dependence and may influence smoking cessation. Therefore, 792 cigarette smokers from the Patch in Practice trial were genotyped for the tryptophan hydroxylase (TPH1 A779C), serotonin transporter (SLC6A45-HTTLPR), and 5-HT1A (HTR1A C-1019G) polymorphisms. Cox regression analysis did not demonstrate significant effects of any of the three genotypes on relapse to smoking: TPH1 (Reference AA; AC: hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.78, 1.24, p=0.90; CC: HR 0.93, 95% CI 0.73, 1.18, p=0.55); 5-HTTLPR (Reference LL; SL: HR 1.01, 95% CI 0.85, 1.20, p=0.90; SS: HR 1.13, 95% CI 0.91, 1.39, p=0.27); HTR1A (Reference CC; CG: HR 1.04, 95% CI 0.86, 1.25, p=0.70; GG: HR 1.01, 95% CI 0.82, 1.24, p=0.93). Moreover, pooled analyses of data from all three extant pharmacogenetic NRT trials (N=1398) found no significant effect of 5-HTTLPR genotype on continuous abstinence at 12-week (Reference LL; SL: odds ratio (OR)=1.25, 95% CI 0.89, 1.74, p=0.19; SS: OR=1.31, 95% CI 0.86, 1.98, p=0.21) or 26-week follow-up (Reference LL; SL: OR=0.93, 95% CI 0.64, 1.33, p=0.68; SS: OR=1.00, 95% CI 0.63, 1.58, p=1.00). These data do not support a statistically or clinically significant moderating effect of these specific 5-HT pathway genetic variants on smoking cessation. However, the possibility remains that other variants in these or other 5-HT genes may influence NRT efficacy for smoking cessation in treatment seeking smokers.

Indexed as

AllelesSmoking CessationAdministration, CutaneousAdultFemaleFollow-Up StudiesGene FrequencyGenotypeHumansMaleMeta-Analysis as TopicMiddle AgedNicotinePharmacogeneticsPolymorphism, Single NucleotideSerotonin Plasma Membrane Transport ProteinsNicotineSerotonin Plasma Membrane Transport ProteinsSLC6A4 protein, humanTPH1 protein, humanTryptophan Hydroxylase

Identifiers

PMID18562131
PMCPMC4439462
OpenAlexW2080089547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.